News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Caron A. Jacobson, MD, Dana-Farber Cancer Institute

Articles by Caron A. Jacobson, MD, Dana-Farber Cancer Institute

R/R Large B-Cell Therapy in Managing Various Lymphomas

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

CAR T-Cell Therapy in Managing Various Lymphomas

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Rationale for Further Development of CAR T-Cell therapy

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Trending on OncLive

Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC

Five Under 5: Top Oncology Videos for the Week of 6/28

The OncFive: Top Oncology Articles for the Week of 6/28

Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma